ANV-600
- Generic Name
- ANV-600
A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Anaveon AG
- Target Recruit Count
- 240
- Registration Number
- NCT06470763
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath